Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05669482 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer

Study acronym: RAMP205
StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 2, 2025 (before its estimated August 31, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Recruiting to Active, Not Recruiting Site details revised at 12 of 12 sitesv27 Show 1 more changeShow less
    • Site details revised at 12 of 12 sites
  2. Primary completion date: May 31, 2025 to Aug 31, 2026 Completion date: Dec 31, 2025 to Aug 31, 2027 · Site contacts updated at 1 of 12 sitesv26 Show 2 more changesShow less
    • Completion date: Dec 31, 2025 to Aug 31, 2027
    • Site contacts updated at 1 of 12 sites
  3. Site contacts updated at 1 of 12 sitesv25
  4. Site contacts updated at 1 of 12 sitesv24
  5. Site contacts updated at 1 of 12 sitesv23
Show 21 earlier versionsHide 21 earlier versions
  1. Site details revised at 1 of 12 sitesv22
  2. Study sites: 11 to 12v21
  3. Site contacts updated at 1 of 11 sitesv20
  4. Site contacts updated at 1 of 11 sitesv19
  5. Study sites: 10 to 11v18
  6. Site details revised at 1 of 10 sitesv17
  7. Site details revised at 1 of 10 sitesv16
  8. Study sites: 8 to 10v15
  9. Site details revised at 1 of 8 sitesv14
  10. Site details revised at 1 of 8 sitesv13
  11. Study sites: 7 to 8v12
  12. Site details revised at 1 of 7 sitesv11
  13. Study sites: 6 to 7v10
  14. Study sites: 5 to 6v9
  15. Study sites: 4 to 5v8
  16. Site details revised at 1 of 4 sitesv7
  17. Study sites: 3 to 4v6
  18. Site details revised at 1 of 3 sitesv5
  19. Site details revised at 1 of 3 sitesv4
  20. Study sites: 1 to 3 Start date changed from estimate of Jan 15, 2023 to Mar 22, 2023v3 Show 1 more changeShow less
    • Start date changed from estimate of Jan 15, 2023 to Mar 22, 2023
  21. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1v2 Show 1 more changeShow less
    • Study sites: 0 to 1
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously untreated.
Trial Details
NCT Number NCT05669482
Lead Sponsor Verastem, Inc.
Conditions KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer, Neoplasms Pancreatic, Malignant Neoplasm of Pancreas
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov